{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:10:22Z","timestamp":1761743422777},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.trim.2010.11.006","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T11:00:49Z","timestamp":1291114849000},"page":"142-148","source":"Crossref","is-referenced-by-count":16,"title":["Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab"],"prefix":"10.1016","volume":"24","author":[{"given":"Shili","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Pao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Vo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Deer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Karasyov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Petrosyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kahwaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Lukovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-Ning","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Aguiluz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Mirocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley C.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieko","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2010.11.006_bb0005","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1034\/j.1600-6143.2003.00121.x","article-title":"Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications","volume":"3","author":"Jordan","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.11.006_bb0010","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trim.2010.11.006_bb0015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trim.2010.11.006_bb0020","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/TP.0b013e3181d21e7f","article-title":"Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation","volume":"89","author":"Vo","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.11.006_bb0025","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.trim.2010.11.006_bb0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-3-540-73259-4_8","article-title":"Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus","author":"Goldblatt","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.trim.2010.11.006_bb0035","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trim.2010.11.006_bb0040","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trim.2010.11.006_bb0045","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1600-6143.2004.00454.x","article-title":"Rituximab as treatment for refractory kidney transplant rejection","volume":"4","author":"Becker","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.11.006_bb0050","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1097\/TP.0b013e3181a6bac5","article-title":"Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection","volume":"87","author":"Fehr","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.11.006_bb0055","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/TP.0b013e31819389cc","article-title":"A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection","volume":"87","author":"Mulley","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.11.006_bb0060","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.transproceed.2008.07.046","article-title":"Rituximab in highly sensitized kidney transplant recipients","volume":"40","author":"Munoz","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2010.11.006_bb0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-0012.2008.00902.x","article-title":"Impact of rituximab therapy for treatment of acute humoral rejection","volume":"23","author":"Kaposztas","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trim.2010.11.006_bb0070","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trim.2010.11.006_bb0075","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trim.2010.11.006_bb0080","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3816\/CLM.2007.n.019","article-title":"Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"7","author":"Harting","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.trim.2010.11.006_bb0085","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-6143.2008.02499.x","article-title":"Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients","volume":"9","author":"Kamar","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.11.006_bb0090","first-page":"3426","article-title":"Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients","volume":"15","author":"Kamar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.11.006_bb0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-6143.2009.02978.x","article-title":"The AJT report: news and issues that affect organ and tissue transplantation. Wrestling with positive cross-matches. A look at some of the newer desensitization therapies","volume":"10","author":"Pondrom","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.11.006_bb0100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1600-6143.2007.02017.x","article-title":"Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab","volume":"8","author":"Vo","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.11.006_bb0105","doi-asserted-by":"crossref","unstructured":"Radha R, Jordan S, Puliyanda D, Bunnapradist S, Petrosyan A, Amet N, et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant. 2005\/01\/08 ed2005. p. 110\u20137.","DOI":"10.1111\/j.1600-6143.2003.00647.x"},{"key":"10.1016\/j.trim.2010.11.006_bb0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/BF01533367","article-title":"Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin","volume":"14","author":"Toyoda","year":"1994","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.trim.2010.11.006_bb0115","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/01.TP.0000165110.78397.93","article-title":"Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients","volume":"80","author":"Toyoda","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.11.006_bb0120","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1399-3046.2008.00904.x","article-title":"Clinical significance of peripheral blood Epstein\u2013Barr viral load monitoring using polymerase chain reaction in renal transplant recipients","volume":"12","author":"Toyoda","year":"2008","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trim.2010.11.006_bb0125","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1046\/j.1523-1755.2001.00727.x","article-title":"Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy","volume":"59","author":"Moudgil","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.trim.2010.11.006_bb0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1874312900802010081","article-title":"Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"2","author":"Feuchtenberger","year":"2008","journal-title":"Open Rheumatol J"},{"key":"10.1016\/j.trim.2010.11.006_bb0135","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trim.2010.11.006_bb0140","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.trim.2010.11.006_bb0145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.trim.2010.11.006_bb0150","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.trim.2010.11.006_bb0155","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trim.2010.11.006_bb0160","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1600-6143.2006.01641.x","article-title":"Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab","volume":"7","author":"Zeevi","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.11.006_bb0165","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/TP.0b013e31819d3353","article-title":"Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up","volume":"87","author":"Clatworthy","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.11.006_bb0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.tp.0000189713.14993.db","article-title":"Campath-1H induction and the incidence of infectious complications in adult renal transplantation","volume":"81","author":"Malek","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.11.006_bb0175","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327410001383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327410001383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T09:42:03Z","timestamp":1685871723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327410001383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0966327410001383"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2010.11.006","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}